Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fetal mesencephalic dopamine neuronal precursor cells are an investigational cell therapy derived from the ventral mesencephalon of fetal tissue. These precursor cells are intended to be transplanted into the brains of patients with Parkinson's disease, specifically into the striatum. The therapeutic goal is for these cells to survive, differentiate into mature dopaminergic neurons, and integrate into the host's neural circuitry to restore dopamine levels and improve motor function. This approach aims to address the progressive loss of substantia nigra dopaminergic neurons, which is the hallmark of Parkinson's disease pathology. Clinical development, such as studies conducted at Bundang CHA Hospital, focus on evaluating the long-term safety, tolerability, and functional efficacy of these transplanted cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fetal mesencephalic dopamine neuronal precursor cells.